http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2603318-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4dd8c727b9b43728cfbf8642e060404 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 |
| filingDate | 2015-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2d4ffca6a122624e48f404300eeeed9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_523f31526261c7e5b49b93f40336e529 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a93a64461ca9cc021793ac204b653c5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddec85eca57ea1cbf96cf50c75d53a97 |
| publicationDate | 2016-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2603318-C1 |
| titleOfInvention | Method of treating occlusion of central vein of retina and its branches |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, n namely to ophthalmology, and aims at treating occlusions of central vein of retina (OCVR) and its branches (OBCVR). Intravitreal introduction of implant Ozurdeks® is made. At reduction of therapeutic effect in period from 3 to 6 months after beginning of treatment introduction of implant Ozurdeks ® is repeated. After 2 weeks laser retinal coagulation in area of edema is made with Nd:YAG laser at wave length of 561 nm, pulse duration 10 ms, power from 70 to 160 mW. At occlusion of central vein of retina 500-2,500 coagulation applications with diameter of 50-300 mcm are applied to edema area with distance between them of 50-450 mcm. In presence of occlusion of temporal branch of central vein of retina 500-1,000 coagulation applications with diameter of 50-300 mcm are applied to edema area with distance between them of 50-450 mcm. In presence of occlusion of macular temporal branches of central vein of retina 100-300 coagulation applications with diameter of 50 mcm are applied to edema area with distance between them of 50-75 mcm. In presence of third-order veins' occlusion 300-1,000 coagulation applications with diameter of 100-300 mcm are applied to edema area with distance between them of 100-450 mcm. n EFFECT: method is simple, minimally invasive, allows to achieve controlled and stable therapeutic effect of intravitreal implant Ozurdeks ® in short period of time with no side effects and postoperative complications; if necessary, method can be used repeatedly, since no inflammatory and cicatrical-sclerotic changes of retinal tissue are observed as result of conducted therapy. n 5 cl, 8 dwg, 4 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2704705-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2696045-C1 |
| priorityDate | 2015-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.